NUVA on NASDAQ

NuVasive

Logo: Lifeofcheetah, CC BY-SA 4.0, via Wikimedia Commons5

American medical device company

NuVasive, Inc. is a medical devices company based in San Diego, California. Founded in 1997, it primarily develops medical devices and procedures for minimally invasive spine surgery. NuVasive's products include software systems for surgical planning and monitoring, access instruments, and implantable hardware.3 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

1997Founded1

Compare with Haemonetics, Embecta Corp. or AbioMed, or pick any stock.

  • TickerNUVA on NASDAQ1
  • IndustrySurgical & Medical Instruments & Apparatus1
  • HeadquartersSan Diego1
  • Websitewww.nuvasive.com
  • Legal formDelaware corporation1
  • Incorporated inDE6
  • Business address7475 Lusk Blvd, San Diego, Ca 921216
  • Filer categoryLarge accelerated filer6
  • LEI549300C5ZB4NZ6TWM8814
  • StatusActive4
  • LEI statusLapsed (not renewed)4
  • Registered addressC/O COGENCY GLOBAL INC., 19904 Dover, United States4
  • Registered withDivision of Corporations, Department of State, 27756174

NuVasive, Inc. is a medical devices company based in San Diego, California. Founded in 1997, it primarily develops medical devices and procedures for minimally invasive spine surgery.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

72.0%Gross margin8
3.4%Net margin8
5.5%Revenue growth, 20228
4.7%Return on equity8
$29.9MFree cash flow8

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Cost of revenue28¢$336.5M
  • Selling, general and admin53¢$634.1M
  • Other costs15¢$179.0M
  • Income tax1¢$11.9M
  • Profit3¢$40.4M

Out of $1.2B in revenue.8

Where each dollar of operating cash went, fiscal 2022

  • Capital spending82¢$139.2M
  • Share buybacks3¢$5.7M
  • Kept or used elsewhere14¢$24.2M

Out of $169.1M of cash from operations.8

Financial statements

Revenue91011128$1.2B in 2022+25% since 2016
0$500.0M$1.0B$1.5B2016: $962.1M$962.1M20162017: $1.0B$1.0B2017+7%2018: $1.1B$1.1B2018+7%2019: $1.2B$1.2B2019+6%2020: $1.1B$1.1B2020−10%2021: $1.1B$1.1B2021+8%2022: $1.2B$1.2B2022+6%
Gross profit91011128$865.4M in 2022+20% since 2016
0$250.0M$500.0M$750.0M$1.0B2016: $722.0M$722.0M20162017: $758.2M$758.2M2017+5%2018: $790.6M$790.6M2018+4%2019: $855.7M$855.7M2019+8%2020: $729.0M$729.0M2020−15%2021: $816.7M$816.7M2021+12%2022: $865.4M$865.4M2022+6%
Net income91011128$40.4M in 2022+9% since 2016
-$100.0M-$50.0M0$50.0M$100.0M2016: $37.2M$37.2M20162017: $81.6M$81.6M2017+119%2018: $12.5M$12.5M2018−85%2019: $65.2M$65.2M2019+423%2020: -$37.2M-$37.2M20202021: -$64.1M-$64.1M2021+72%2022: $40.4M$40.4M2022
Fiscal year2016201720182019202020212022
Revenue$962.1M9$1.0B10$1.1B11$1.2B12$1.1B8$1.1B8$1.2B8
Cost of revenue$240.1M9$268.4M10$311.2M11$312.4M12$321.6M8$322.3M8$336.5M8
Gross profit$722.0M9$758.2M10$790.6M11$855.7M12$729.0M8$816.7M8$865.4M8
Research and development$48.0M9$50.4M10$61.7M11$72.4M12$79.8M12$92.6M12
Selling, general and admin$533.6M9$539.5M10$575.8M11$611.2M12$547.2M8$610.1M8$634.1M8
Operating expenses$828.7M8$777.0M8
Income before tax-$58.4M8$52.3M8
Income tax$29.3M9-$7.5M10-$3.8M11$15.3M12-$10.4M8$5.7M8$11.9M8
Net income$37.2M9$81.6M10$12.5M11$65.2M12-$37.2M8-$64.1M8$40.4M8
Earnings per share$0.749$1.6010$0.2411$1.2612-$0.728-$1.248$0.788
Earnings per share (diluted)$0.699$1.4810$0.2411$1.2312-$0.728-$1.248$0.768
Shares (weighted, basic)51.6M shares852.0M shares8
Shares (weighted, diluted)51.6M shares857.4M shares8

Compare NuVasive with another company

Corporate structure

NuVasive sits at the top of its group. 2 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of NuVasive

  • NuVasive San Diego, California, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G; stakes of 5% or more it reported on Schedules 13D and 13G (1 companies). Each entity in the chart links to its source.

What it owns

What NuVasive reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$919.7M8 Dec 31, 2022$806.2M8 Dec 31, 2021+14.1%
Accumulated depreciation$573.2M8 Dec 31, 2022$502.5M8 Dec 31, 2021+14.1%
Property and equipment, net$346.5M8 Dec 31, 2022$303.7M8 Dec 31, 2021+14.1%
Finance-lease assets$1.9M8 Dec 31, 2022$2.3M8 Dec 31, 2021−16.8%
Operating-lease assets (leased space)$95.1M8 Dec 31, 2022$103.0M8 Dec 31, 2021−7.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$248.7M8 Dec 31, 2022$246.1M8 Dec 31, 2021+1.0%
Equity securities at fair value$3.5M8 Dec 31, 2022

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$639.7M8 Dec 31, 2022$633.5M8 Dec 31, 2021+1.0%
Intangible assets, net (excluding goodwill)$184.3M8 Dec 31, 2022$242.7M8 Dec 31, 2021−24.1%
Finite-lived intangibles, gross$626.3M8 Dec 31, 2022$635.0M8 Dec 31, 2021−1.4%
Accumulated amortization$444.5M8 Dec 31, 2022$392.3M8 Dec 31, 2021+13.3%
Finite-lived intangibles, net$181.8M8 Dec 31, 2022$242.7M8 Dec 31, 2021−25.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$338.6M8 Dec 31, 2022$315.8M8 Dec 31, 2021+7.2%
Raw materials$6.7M8 Dec 31, 2022$6.4M8 Dec 31, 2021+4.7%
Work in process$5.8M8 Dec 31, 2022$8.1M8 Dec 31, 2021−28.4%
Finished goods$326.1M8 Dec 31, 2022$301.3M8 Dec 31, 2021+8.2%

The story

NuVasive incorporated on July 21, 1997, as a medical device company in San Diego, California. The NuVasive approach to Minimally Invasive Surgery (MIS) was a new surgical platform called Maximum Access Surgery (MAS). The flagship procedure is the XLIF (eXtreme Lateral Interbody Fusion) procedure, a minimally disruptive procedure that allows spine surgeons to have direct access to the intervertebral space from the side of the body, as opposed to the front or back. Their patient support division is called The Better Way Back.

NuVasive acquired the LessRay product from SafeRay Spine and launched the product in 2018 as a fluoroscopy system that enhances the clarity of radiographic images. They provide medical equipment, surgical support, and necessary funds to those in need of spine surgery around the world through the NuVasive Spine Foundation.

In May 2013, NuVasive acquired a small manufacturer, ANC LLC (located in Fairborn, Ohio) for $4.5 million. This decision to start making its own spinal-care devices eventually lead them to open a larger manufacturing facility in West Carrollton, Ohio. They fully moved all manufacturing to this larger facility in early 2018 employing roughly 300 by 2024. This new segment of Nuvasive, as an in-house parts maker called Nuvasive Manufacturing, LLC., is also known to keep a robust inventory of white boards in their effort to insource.

From Wikipedia’s article on NuVasive, shared under CC BY-SA 4.0.7

Leadership

Who has led NuVasive, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (44)

Products and brands

NuVasive has three business segments: Spine, Orthopedics (NuVasive Specialized Orthopedics), and Neuromonitoring (NuVasive Clinical Services).

From Wikipedia’s article on NuVasive, shared under CC BY-SA 4.0.7

Acquisitions

In 2016, Biotronic NeuroNetwork and Ellipse Technologies were acquired by NuVasive. In 2017, Vertera Spine and SafePassage were acquired by NuVasive. In 2021, NuVasive acquired Simplify Medical.

From Wikipedia’s article on NuVasive, shared under CC BY-SA 4.0.7

Timeline

  1. Sep 1, 20238-K Entered a material agreement; Ended a material agreement; Completed an acquisition or sale75
  2. Aug 2, 20238-K Results of operations; Regulation FD disclosure76
  3. Jun 9, 20238-K Shareholder vote77
  4. Jun 2, 20238-K Other events78
  5. May 26, 20238-K New debt or obligation79
  6. May 10, 20238-K Entered a material agreement; Results of operations; New debt or obligation80
  7. May 3, 20238-K Other events81
  8. Apr 27, 20238-K Shareholder vote; Other events82
  9. Apr 17, 20238-K Other events83
  10. Apr 4, 20238-K Regulation FD disclosure84
  11. Apr 3, 20238-K Other events85
  12. Feb 22, 20238-K Results of operations; Regulation FD disclosure86
  13. Feb 19, 2016New chief executive Edmund J. Roschak becomes CEO16
  14. May 28, 2015New chief executive Gregory T. Lucier becomes CEO17
  15. Jan 5, 2006New chief executive Alexis Lukianov V. becomes CEO18
  16. 1997Founded Founded1

Calendar

When it reported results

  1. Aug 2, 2023Reported quarterly or annual results76
  2. May 10, 2023Reported quarterly or annual results80
  3. Feb 22, 2023Reported quarterly or annual results86
  4. Feb 9, 2023Reported quarterly or annual results87
  5. Nov 9, 2022Reported quarterly or annual results88
  6. Aug 3, 2022Reported quarterly or annual results89
  7. May 4, 2022Reported quarterly or annual results90
  8. Feb 23, 2022Reported quarterly or annual results91

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

154 filings to the SEC since October 2021: 3 annual reports, 6 quarterly reports, 25 major events, 56 insider forms, 12 large holders, 52 other. The latest 20:

  1. Sep 11, 202315-12G EDGAR
  2. Sep 11, 2023SC 13G/A SCHEDULE 13G/A EDGAR
  3. Sep 7, 2023EFFECT EDGAR
  4. Sep 7, 2023EFFECT EDGAR
  5. Sep 7, 2023EFFECT EDGAR
  6. Sep 7, 2023EFFECT EDGAR
  7. Sep 7, 2023EFFECT EDGAR
  8. Sep 7, 2023EFFECT EDGAR
  9. Sep 7, 2023SC 13G/A EDGAR
  10. Sep 5, 20234 FORM 4 SUBMISSION EDGAR
  11. Sep 5, 20234 FORM 4 SUBMISSION EDGAR
  12. Sep 5, 20234 FORM 4 SUBMISSION EDGAR
  13. Sep 5, 20234 FORM 4 SUBMISSION EDGAR
  14. Sep 5, 20234 FORM 4 SUBMISSION EDGAR
  15. Sep 5, 20234 FORM 4 SUBMISSION EDGAR
  16. Sep 5, 20234 FORM 4 SUBMISSION EDGAR
  17. Sep 5, 20234 FORM 4 SUBMISSION EDGAR
  18. Sep 5, 20234 FORM 4 SUBMISSION EDGAR
  19. Sep 5, 20234 FORM 4 SUBMISSION EDGAR
  20. Sep 5, 20234 FORM 4 SUBMISSION EDGAR

The 154 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 0 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Apr 13, 2022Barry James ChristopherChief Executive OfficerSale5,000$58.00$290.0KForm 4
Mar 28, 2022Barry James ChristopherChief Executive OfficerSale5,000$55.00$275.0KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Stakes it holds

NuVasive has told the SEC it owns more than 5% of 1 company, latest first (Schedules 13D and 13G).

SEC filer profile

How NuVasive is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNUVASIVE INC2
  • CIK0001142596
  • Employer ID (EIN)33-07685982
  • Filer statusLarge accelerated filer2
  • Incorporated inDelaware2
  • Fiscal year endsDecember 312
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus2
  • Business address7475 Lusk Blvd, San Diego, CA 921212
  • Phone(858) 909-18002
  • Shares outstanding52,449,167 as of Jul 31, 202314
  • Public float$2.6B as of Jun 30, 202299
  • On EDGAR sinceJul 1, 20032
  • Filings1,867 in all: 4 (1,083), 8-K (270), SC 13G/A (87), 3 (77), 10-Q (58), SC 13G (36), 4/A (32), 425 (23)2
    All 46 form types

    DEF 14A (21), 10-K (19), DEFA14A (16), CT ORDER (15), SD (10), UPLOAD (10), EFFECT (9), ARS (8), S-8 (8), S-8 POS (8), 5 (7), POS AM (7), 8-K/A (6), CORRESP (6), S-3 (5), 3/A (4), 424B1 (4), POSASR (4), S-1/A (4), S-3ASR (4), FWP (3), 10-K/A (2), 424B4 (2), PRE 14A (2), S-3/A (2), SC 13D (2), SC 13D/A (2), 15-12G (1), 25-NSE (1), 424B5 (1), 8-A12G (1), D (1), DEFM14A (1), DEFR14A (1), REGDEX (1), REGDEX/A (1), S-1 (1), S-3MEF (1)

  • Latest filingsAnnual report (10-K) Feb 22, 2023
    Quarterly report (10-Q) Aug 2, 2023
    Proxy statement (DEF 14A) May 8, 2023
    Latest 8-K (8-K) Sep 1, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
    SEC EDGAROther events
  79. 79
  80. 80
  81. 81
    SEC EDGAROther events
  82. 82
  83. 83
    SEC EDGAROther events
  84. 84
  85. 85
    SEC EDGAROther events
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
  96. 96
  97. 97
  98. 98
  99. 99